Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND: Tezacaftor/Ivacaftor in CF with Residual Function
NCT02392234Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of tezacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Mar 2015; status: completed.
02
Drugs
tezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02392234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392234.